NO904294D0 - Preparat og fremgangsmaate for aa fremskynde lysis av blodkoagel. - Google Patents

Preparat og fremgangsmaate for aa fremskynde lysis av blodkoagel.

Info

Publication number
NO904294D0
NO904294D0 NO1990904294A NO904294A NO904294D0 NO 904294 D0 NO904294 D0 NO 904294D0 NO 1990904294 A NO1990904294 A NO 1990904294A NO 904294 A NO904294 A NO 904294A NO 904294 D0 NO904294 D0 NO 904294D0
Authority
NO
Norway
Prior art keywords
lysis
clois
preparations
procedures
hapten
Prior art date
Application number
NO1990904294A
Other languages
English (en)
Other versions
NO301374B1 (no
NO904294L (no
Inventor
Guy L Reed
Gary Matsueda
Edgar Haber
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of NO904294D0 publication Critical patent/NO904294D0/no
Publication of NO904294L publication Critical patent/NO904294L/no
Publication of NO301374B1 publication Critical patent/NO301374B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Surgical Instruments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
NO904294A 1988-04-04 1990-10-03 Fremgangsmåte for fremstilling av et <alfa>2-antiplasmin monoklonalt antistoff NO301374B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17722288A 1988-04-04 1988-04-04
PCT/US1989/001065 WO1989009817A1 (en) 1988-04-04 1989-03-15 Composition and method for acceleration of clot lysis

Publications (3)

Publication Number Publication Date
NO904294D0 true NO904294D0 (no) 1990-10-03
NO904294L NO904294L (no) 1990-12-04
NO301374B1 NO301374B1 (no) 1997-10-20

Family

ID=22647707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO904294A NO301374B1 (no) 1988-04-04 1990-10-03 Fremgangsmåte for fremstilling av et <alfa>2-antiplasmin monoklonalt antistoff

Country Status (15)

Country Link
EP (1) EP0336693B1 (no)
JP (1) JP2871775B2 (no)
KR (1) KR100194113B1 (no)
AT (1) ATE114480T1 (no)
AU (1) AU628041B2 (no)
CA (1) CA1341377C (no)
DE (1) DE68919504T2 (no)
DK (1) DK174062B1 (no)
ES (1) ES2064435T3 (no)
FI (1) FI102812B1 (no)
GR (1) GR3015182T3 (no)
HU (1) HU207349B (no)
NO (1) NO301374B1 (no)
WO (1) WO1989009817A1 (no)
ZA (1) ZA892464B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JPH02268694A (ja) * 1989-04-07 1990-11-02 Teijin Ltd 血栓溶解剤
JP2001515345A (ja) * 1996-09-20 2001-09-18 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対する抗体を用いてフィブリン溶解を増進するための組成物と方法
US6524675B1 (en) 1999-05-13 2003-02-25 3M Innovative Properties Company Adhesive-back articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735340B2 (ja) * 1985-05-23 1995-04-19 帝人株式会社 血栓溶解促進剤
DE3751907T2 (de) * 1986-05-15 1997-04-03 Univ Emory Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie

Also Published As

Publication number Publication date
JP2871775B2 (ja) 1999-03-17
KR100194113B1 (ko) 1999-06-15
DK174062B1 (da) 2002-05-13
HU892304D0 (en) 1991-07-29
ES2064435T3 (es) 1995-02-01
AU628041B2 (en) 1992-09-10
FI102812B (fi) 1999-02-26
ATE114480T1 (de) 1994-12-15
NO301374B1 (no) 1997-10-20
EP0336693A3 (en) 1990-03-21
HU207349B (en) 1993-03-29
AU3284589A (en) 1989-11-03
NO904294L (no) 1990-12-04
WO1989009817A1 (en) 1989-10-19
DE68919504D1 (de) 1995-01-12
GR3015182T3 (en) 1995-05-31
JPH03504717A (ja) 1991-10-17
DE68919504T2 (de) 1995-06-29
ZA892464B (en) 1989-12-27
EP0336693B1 (en) 1994-11-30
DK240190A (da) 1990-10-04
EP0336693A2 (en) 1989-10-11
FI904867A0 (fi) 1990-10-03
HUT56394A (en) 1991-08-28
DK240190D0 (da) 1990-10-04
KR900700129A (ko) 1990-08-11
FI102812B1 (fi) 1999-02-26
CA1341377C (en) 2002-07-16

Similar Documents

Publication Publication Date Title
Lijnen et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
Reed et al. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism
FI911049A0 (fi) Vaevnadsplasminogenaktivator med zymogena eller fibrinspecifika egenskaper.
BG101647A (en) Low molecular weight bicyclic thrombin inhibitors
BR9708859A (pt) Composto uso do mesmo composição para inibir formação de trombo em sangue e processos para inibir trombina e formação de agregados de plaquetas sanguíneas e de trombo no sangue para tratar ou evitar tromboemolismo venoso e embolismo pulmonar trombose tromboembolismo cardiogênico acidente vascular cerebral trombose angina instável infartação miocárdica aterosclerose distúrbio cardaco isquêmico reoclus o restenose oclus o de enxertos de derivação de artéria coronária e doença cerebrovascular oclus
NO904294D0 (no) Preparat og fremgangsmaate for aa fremskynde lysis av blodkoagel.
Kowalski et al. Circulating fibrinogen degradation products (FDP) in dog blood after intravenous thrombin infusion
Verstraete Use of thrombolytic drugs in non-coronary disorders
Marie-Claude Effect of rabbit thrombomodulin on thrombin inhibition by antithrombin in the presence of heparin
Marci et al. A review of the clinical indications for the plasma heparin assay
Eisenberg Role of new anticoagulants as adjunctive therapy during thrombolysis
Lijnen et al. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis
Kasper et al. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase
Jang et al. A randomized, blinded study of two doses of Novastan®(brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study
Henriksson et al. Fatal iron intoxication with multiple coagulation defects and degradation of factor VIII and factor XIII
Bang Tissue-type plasminogen activator mutants. Theoretical and clinical considerations.
Spriggs et al. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model
ATE113983T1 (de) Gewebeplasminogenaktivator mit fibrin- spezifischen eigenschaften.
Boeve et al. Comparison of argatroban and hirudin for the reperfusion of thrombotic arterial occlusion by tissue plasminogen activator
Preissner et al. Influence of fibrinogen on fibrin polymerization. Ultracentrifugation studies
Blix The euglobulin method for estimation of fibrinolytic activity in urokinase-activated plasma, and the influence of Trasylol
Konttinen The effect of streptokinase on the plasma heparin thrombin time
Norman III. INHIBITORS OF THE FIBRINOLYTIC SYSTEM
DK0563280T3 (da) Vævsplasminogenaktivator substitutionsvariant

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees